BACKGROUND: Incidence of malignant brain tumor varies significantly by country. The variation in incidence may point to differences in risk for brain tumor by ancestry, as well as differences in cancer registry data collection. We examined regional differences as well as differences between developed economies and developing economies. METHODS: Using data from the Central Brain Tumor Registry of the United States (CBTRUS, ~99.9% of all US) and the International Agency for Research on Cancer (IARC)'s Cancer Incidence in Five Continents X, which contains data ranging from 2003-2007 from over 300 cancer registries, we calculated the average annual age-adjusted incidence rates (AAIR) per 100,000 population of brain and CNS tumors. RESULTS: There were significant differences in incidence of malignant brain tumors by country. Overall incidence of malignant brain tumor in the US was 7.26 in males, and 5.37 in females. Incidence was lower in Egypt (Male AAIN=4.3, Female AAIN=3.2), Brazil (Sao Paulo, Male AAIN=6.1, Female AAIN=4.6). In China, incidence was higher in females (AAIN=6.2), but lower in males (AAIN=5.4). Incidence in females was highest in Sweden (AAIN=11.0), and incidence in males was highest in Serbia (AAIN=10.5). CONCLUSION: Brain and CNS tumors are a significant source of cancer-related morbidity and mortality worldwide. Regional differences may provide clues toward genetic or environmental causes. Gaining a comprehensive understanding of the epidemiology of malignant brain tumors globally is critical to researchers, public health officials, disease interest groups and clinicians, and contributes to the direction of future research. A role for neurotropic viruses in glioma etiology is supported by epidemiologic and clinical observations. Glioma patients consistently report a lower history of clinical responses to Varicella (VZV, chickenpox and shingles), and prior evidence suggests that strong varicella responses are toxic to glioma cells. We hypothesized that patient-restricted response to Varicella virus may impact efficacy of immune response against glioma, affecting incidence of the disease as well as survival in those afflicted. We explored the serum antibody viral protein-restricted response against 99 VZV protein antigens using Nucleic Acid Programmable Protein Arrays (NAPPA) in prediagnostic serum samples from 131 glioma patients and 524 controls from the Prostate Lung Colorectal and Ovarian Cancer Cohort. Multivariable analyses were constructed to include all protein antigens, and covariates such as education, gender, and number of days from blood draw to diagnosis. Stepwise regression indicated a reduced risk for subjects with a response against Orf68 (glycoprotein E), the most abundant glycoprotein in varicella (OR = 0.39, 95% CI = 0.19-0.81, P = 0.02). When incorporating glioma clinical grade in statistical models, serum responses were significantly different by grade for proteins Orf20 (capsid protein), Orf26 (packaging protein), and Orf31 (envelope glycoprotein). These specific responses, particularly that of glycoprotein E, point towards immunologic targets for glioma prevention. Future research will map the most reactive peptides within the glycoprotein E protein.
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EPID-07. GLIOBLASTOMA SURVIVAL IN RELATION TO SOCIO-DEMOGRAPHIC AND ECONOMIC FACTORS; A SURVEILLANCE EPIDEMIOLOGY AND END RESULTS ANALYSIS
Kimberly Johnson, MPH, PhD, Kazi Ahsan, Jong Min Lee, Timothy McBride and Jian Campian; Washington University, St. Louis, MO, USA BACKGROUND: It is well-established that socio-demographic and economic factors affect health outcomes. However, there has been limited analysis using population-based data on the independent effects of factors such as race, marital status, place of residence and insurance status on glioblastoma (GBM) survival. Our objective was to examine the effect of these factors on GBM survival. METHODS: Individuals aged <65 years old who were diagnosed with a GBM (ICD-O-3 codes: 9440-9443) during 2007-2013 from the Surveillance Epidemiology and End Results 18 database were ascertained for the analysis. We used Cox proportional hazards regression models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for the effect of several factors on GBM survival. RESULTS: A total of 9,388 individuals met inclusion criteria. After adjusting for age at diagnosis, race, sex, and county percent of families living below poverty, those with any Medicaid, insurance status unknown and those who were uninsured had significantly higher hazards of GBM death with HRs of 1.32 (95% CI 1.23-1.43), 1.35 (95% CI 1.16-1.58), and 1.27 (95% CI 1.14-1.40) compared to those with insurance at diagnosis, respectively. Unmarried individuals aged >19 years at diagnosis had a significantly increased HR for GBM death compared to those who were married (HR=1.19; 95% CI 1.12-1.26). In those <19 years old at diagnosis (n=255), individuals with Black race had a significantly increased risk of GBM death compared to those with White race (HR=1.75; 95% CI 1.14-2.68). Finally, individuals living in counties in the highest relative to the lowest family poverty quartile had a significantly increased hazard of GBM death (HR=1.20; 95%CI 1.11-1.30). CONCLUSIONS: Socio-demographic and economic factors significantly affect GBM survival, one of the most lethal cancers. Addressing factors underlying these associations may result in an improvement in GBM survival time and reduce health disparities. (2000) (2001) (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) . Surgical treatment was categorized into gross total resection (GTR) and no GTR. Log-rank test and multivariate Cox proportional hazard modeling were used to examine treatment effect on overall survival (OS). On univariate analysis, GTR was associated with improved OS for ependymoma (89% vs. 81%, p<0.01) and similar trend was observed for myxopapillary ependymoma (97% vs. 94%, p=0.13), subependymoma (93% vs. 89%, p=0.37), anaplastic ependymoma (50% vs. 26%, p=0.10). In multivariate analysis adjusting for age, sex, race, marital status, and year of diagnosis, GTR was associated with significantly improved OS for ependymoma (HR 0.711, 95% CI 0.527-0.953, p=0.02) but only a trend toward OS for anaplastic ependymoma (HR 0.703, 95% CI 0.426-1.145, p=0.16). Using multivariate analysis, adjuvant RT was found to associate with worse OS for ependymoma (HR 2.049, 95% CI 1.207-3.387, p=0.01), and no association was observed for the other histological groups. Among all prognostic factors, advanced age was determined to most significantly affect OS for all 4 histological groups: for age group 60-74 (compared to age group 18-44), myxopapillary ependymoma (HR 17.661, 95% CI 4.326-82.000, p<0.01), subependymoma (HR 4.932, 95% CI 1.522-19.044, p=0.01), ependymoma (HR 5.943, 95% CI 3.967-8.996, p<0.01), anaplastic ependymoma (HR 3.076, 95% CI 1.389-6.520, p=0.01). Ependymoma was the most common histological subtype among all ependymal tumors in the United States. Age at diagnosis was found to significantly contribute to patient long term survival. Surgery in the format of GTR provided survival benefit particularly in ependymoma.
EPID-08. TREATMENT OUTCOME FOR EPENDYMAL TUMORS IN THE UNITED STATES
EPID-09. INCIDENCE OF GLIOMA IN A MIXED URBAN-RURAL COMMUNITY OF NORTH AMERICA: A POPULATION-BASED STUDY
Conor Ryan, Harsheen Kaur, Chung-Il Wi, Euijung Ryu, Katherine King, Young Juhn and Daniel Lachance; Mayo Clinic, Rochester, MN, USA BACKGROUND: Limited information is known about incidence trends of glioma and its characteristics in well-defined populations, especially in a mixed urban-rural setting of North America. We assessed glioma incidence and characterized it in the Olmsted County, Minnesota, population. METHODS: This population-based study utilized the Mayo Clinic Tumor Registry and the Rochester Epidemiology Project (NIH-funded medical record linkage system for Olmsted County residents). We assessed incidence of pathologically confirmed glioma between January 1, 1995, and December 31, 2014. Age-and gender-adjusted incidence rates per 100,000 person-years were calculated using the 2010 US white population. We compared incidence trends of glioma during our study period with Olmsted County data from . World Health Organization grading was used. RESULTS: We identified 135 incident glioma cases (93% white) with 20 pediatric cases (< 20 years at diagnosis) (50% female) and 115 adult cases (≥20 years at diagnosis) (44% female). The overall incidence rate (all ages) during our study period, 5.5, was the same as that in 1950-1990, 5.5 . Adult males, 7.87, had a higher rate than females, 5.23. Incidence of pediatric (age <20) glioma was 2.5 (95% CI: 1.4-3.6) and 1.5 for Grade I astrocytoma (60% of pediatric cases). Adult glioma was 6.5 (95% CI: 5.3-7.7) overall and 4.3 for glioblastoma. Incidence rates increased from 2.11 for age 20-29 years to 11.51 for age 60+ years, most noticeably increasing after age 50. Glioblastoma became the predominant tumor type after age 40 (77%), while occurring in only 12% of adults <40 years. Majority (68%) of tumors in ages 20-39 were grade II/III. CONCLUSIONS: Given its methodology, this study likely offers the most reliable data for (1) assessing incidence of glioma by grade, and (2) trending glioma incidence, which appears stable to studies from this population dating back to 1950. BACKGROUND: Germline alterations near TERC, TERT, EGFR, CCDC26, CDKN2A/B, VTI1A, ZBTB16, PHLDB1, POLR3B, ETFA, TP53 and RTEL1 are associated with glioma risk. Additionally, particular molecular groups of glioma are associated with SNPs with clinically-relevant odds ratios. For example, rs55705857 (CCDC26) is associated with >6-fold risk of developing gliomas that acquire IDH mutations. We recently demonstrated that five clinically-relevant groups of gliomas can be defined by TERT promoter mutation, IDH1/2 mutation and 1p/19q codeletion. Thus, we evaluated each of the currently known glioma risk SNPs with each of these five groups. METHODS: Germline SNPs in 2157 glioma cases and 674 controls from Mayo Clinic and UCSF were genotyped using the custom Illumina Oncoarray developed by the Glioma International Case Control Consortium. Glioma cases were classified into five molecular groups based on TERT promoter mutation, IDH1/2 mutation and 1p/19q co-deletion. The groups were denoted as triple-negative, IDH-mutation only, TERT-mutation only, IDH and TERT mutations and triple-positive. Within each molecular group, additive logistic regression was used to assess the association of each SNP with disease status, adjusted for age, gender and site. RESULTS: Of the 2157 gliomas (867 GBM and 1290 nonGBM), 961 had sufficient molecular data for classification into a molecular group: 90 triple-negative, 238 IDHmutation only, 410 TERT-mutation only, 36 IDH and TERT mutations and 187 triple-positive. Using alpha=0.01, TERT-mutation only gliomas were predominantly associated with TERT, CDKN2A/B and RTEL1 SNPs, while triple-positive gliomas were predominantly associated with ZBTB16 and ETFA SNPs. All groups with an IDH mutation were associated with the CCDC26 SNP and all molecular groups were associated with the TP53 SNP. CONCLUSIONS: Our results suggest that known glioma risk SNPs are often specific to a particular molecular subtype of glioma. We are currently obtaining additional cases and controls in order to increase statistical power for the smaller groups. BACKGROUND: IDH1/2 mutated glioma is associated with the presence of a germline risk variant, the rs55705857 G allele. The Utah Population Database (UPDB) is a unique prospective resource for evaluating cancer risk in related individuals. We aimed to determine the risk of glioma and other cancers in relatives of patients with IDH1/2 mutant glioma based on rs55705857 alleles. METHODS: Patients with IDH1/2 mutant or 1p/19q co-deleted glioma were identified. Samples of either blood or tumor were obtained from the Huntsman Cancer Institute Cancer Clinical Research Database. For those people with DNA available from both blood and tumor, we compared the genotyping results to determine if tumor accurately represents rs55705857 genotype. One hundred and two individuals were genotyped and linked to the UPDB. We determined congruence between somatic and germline samples and estimated the relative risk (RR) to first and second-degree relatives of G allele carriers to develop cancers associated with IDH1/2 mutations. RESULTS: Somatic DNA had 85.7 % Sensitivity (CI 57.2%-98.2%) and 95.8 % Specificity (CI 78.9%-99.89%) for the rs55705857 G allele. Forty-one patients linked to threegeneration pedigrees in the UPDB. First-degree relatives of rs55705857 G allele carrier patients are at significantly increased risks for developing any cancer (RR = 1.72, p=0.045, CI 1.02-2.94), and specifically oligodendroglioma (RR= 57.61, p=0.017, CI 2.96-320.98) or prostate cancer (RR= 4.10, p=0.008, CI 1.62-9.58), but relatives of people without the rs55705857 G allele are not at increased risk. Second-degree relatives of G allele carriers also had an overall increased risk for developing cancer (RR = 1.50, p=0.007, CI 1.15-2.01). CONCLUSIONS: Tumor DNA accurately reflects rs55705857 genotype. The G allele at this locus confers an increased risk of all cancers and of oligodendroglioma in relatives. No increased cancer or brain tumor risk was seen in family members of people without the G allele SNP rs55705857.
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